FISCAL NOTE

Requested by Legislative Council 02/14/2013

Revised

Amendment to: SB 2190

1 A. **State fiscal effect:** Identify the state fiscal effect and the fiscal effect on agency appropriations compared to funding levels and appropriations anticipated under current law.

| levels and appropriations anticipated under earrent law. | | | | | | | | |
|--|--------------------|-------------|--------------------|-------------|--------------------|-------------|--|--|
| | 2011-2013 Biennium | | 2013-2015 Biennium | | 2015-2017 Biennium | | | |
| | General Fund | Other Funds | General Fund | Other Funds | General Fund | Other Funds | | |
| Revenues | | | | | | | | |
| Expenditures | | | | | | | | |
| Appropriations | | | | | | | | |

1 B. County, city, school district and township fiscal effect: Identify the fiscal effect on the appropriate political subdivision.

| | 2011-2013 Biennium | 2013-2015 Biennium | 2015-2017 Biennium |
|------------------|--------------------|--------------------|--------------------|
| Counties | | | |
| Cities | | | |
| School Districts | | | |
| Townships | | | |

2 A. **Bill and fiscal impact summary:** Provide a brief summary of the measure, including description of the provisions having fiscal impact (limited to 300 characters).

SB2190 allows a pharmacy to substitute biosimilars for a prescribed product only if requirements are met and gives individuals the right to refuse the biosimilar chosen by the pharmacist. Biosimilars are less costly; therefore, adding requirements to dispense biosimilars may increase Medicaid costs.

B. **Fiscal impact sections**: *Identify and provide a brief description of the sections of the measure which have fiscal impact. Include any assumptions and comments relevant to the analysis.*

Section 1 allows a pharmacy to substitute biosimilars for a prescribed product only if specific requirements are met; and gives individuals the right to refuse the biosimilar chosen by the pharmacist. Biosimilars are less costly; therefore, adding requirements to dispense biosimilars may increase Medicaid costs. The potential increase to the Medicaid program budget cannot be determined.

- 3. State fiscal effect detail: For information shown under state fiscal effect in 1A, please:
 - A. **Revenues:** Explain the revenue amounts. Provide detail, when appropriate, for each revenue type and fund affected and any amounts included in the executive budget.
 - B. **Expenditures:** Explain the expenditure amounts. Provide detail, when appropriate, for each agency, line item, and fund affected and the number of FTE positions affected.
 - C. **Appropriations:** Explain the appropriation amounts. Provide detail, when appropriate, for each agency and fund affected. Explain the relationship between the amounts shown for expenditures and appropriations. Indicate whether the appropriation is also included in the executive budget or relates to a continuing appropriation.

Name: Paul R. Kramer

Agency: Department of Human Services

Telephone: 701-328-1980

Date Prepared: 03/18/2013